# A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults

> **NCT05091307** · PHASE3 · COMPLETED · sponsor: **Janssen Vaccines & Prevention B.V.** · enrollment: 861 (actual)

## Conditions studied

- COVID-19 Prevention

## Interventions

- **BIOLOGICAL:** Ad26.COV2.S
- **OTHER:** Placebo
- **BIOLOGICAL:** Influenza Vaccine

## Key facts

- **NCT ID:** NCT05091307
- **Lead sponsor:** Janssen Vaccines & Prevention B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-02
- **Primary completion:** 2022-06-17
- **Final completion:** 2022-11-15
- **Target enrollment:** 861 (ACTUAL)
- **Last updated:** 2025-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05091307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05091307, "A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05091307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*